The Efficacy and Safety of DLBS3233 in Adults With Prediabetes
brief summary
This is a 3-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing DLBS3233 at a dose of 100 mg once daily; DLBS3233 at a dose of 200 mg once daily; and Metformin XR 500 mg twice daily for a 12-week course of therapy. DLBS3233 is a bioactive fraction derived from a combination of Lagerstroemia speciosa and Cinnamomum burmanii. DLBS3233 exhibits antidiabetic properties by enhancing insulin signaling, improving glucose uptake, modulating lipid metabolism, and reducing insulin resistance.
detailed description
There will be 3 groups of treatment; each group will consist of 40 subjects with the treatment regimens for 12 weeks:
Treatment I : 1 capsule of DLBS3233 1000 mg once daily; Treatment II : 2 capsules of DLBS3233 100 mg once daily; Treatment III : 1 tablet of Metformin XR 500 mg twice daily
Subjects will be asked to come to the clinic and will be evaluated for treatment efficacy at Baseline and at 4-week intervals over the 12-week course of therapy. Throughout the 12-week therapy, subjects should record the product consumption and adverse event occurred during the study in the provided Patient's Diary.
The safety profile of study medication other than vital signs and adverse event will be measured at Baseline and End of Study.
official title
A Randomized, Double-Blind, Parallel, Controlled, Non-Inferiority Study to Evaluate the Efficacy and Safety of DLBS3233 in Adults With Prediabetes